Potentiation of the biological efficacy of bradykinin by ACE inhibitors: A shift in the affinity of the B2 receptor?

Immunopharmacology

Volumn 33, Issue 1-3, 1996, Pages 93-94

  Hecker, Markus ^a   Bara, Agnieszka T ^a   Busse, Rudi ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

ACE inhibitor; bradykinin B2 receptor; rabbit jugular vein

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 3,4 DICHLOROISOCOUMARIN; ANGIOTENSIN; APSTATIN; BRADYKININ; BRADYKININ B2 RECEPTOR; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HIPPURYLHISTIDYLLEUCINE; MOEXIPRILAT; PHOSPHORAMIDON; PROTEINASE INHIBITOR; QUINAPRILAT; RAMIPRILAT; UNCLASSIFIED DRUG;

ANIMAL TISSUE; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; ENZYME SUBSTRATE; JUGULAR VEIN; NONHUMAN; PRIORITY JOURNAL; RABBIT; RECEPTOR AFFINITY; VASODILATATION; VENOCONSTRICTION;

EID: 0030176097     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/0162-3109(96)00018-5     Document Type: Conference Paper

References (2)

1. Auch-Schwelk W, Bossaller C, Claus M, Graf K, Gräfe M, Fleck E. ACE inhibitors are endothelium-dependent vasodilators of coronary arteries during submaximal stimulation with bradykinin. Cardiovasc Res 1993; 27: 312-317.
2. Hecker M, Pörsti I, Bara AT, Busse R. Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation - interaction at the receptor level. Br J Pharmacol 1994; 111: 238-244.